Insights

Gathering insights about Fulcrum…

Similar companies to Fulcrum

Fulcrum Tech Stack

Media & News

Acadian Asset Management LLC Grows Stake in Fulcrum Therapeutics, Inc. $FULC
Acadian Asset Management LLC raised its position in Fulcrum Therapeutics, Inc. (NASDAQ: FULC) by 63.5% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 563,380 shares of the company's stock after purchasing an additional 218,819 shares during the period. Acadian Asset Management LLC owned 1.04%
Nov 14, 2025 | www.defenseworld.net
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
Nov 07, 2025 | www.globenewswire.com
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
― Pociredir Phase 1b PIONEER Trial Data in Sickle Cell Disease to be Presented and Published, Including 12 mg and 20 mg Cohorts ―
Nov 03, 2025 | www.globenewswire.com
Fulcrum Therapeutics, Inc. (FULC) Q3 2025 Earnings Call Transcript
Fulcrum Therapeutics, Inc. ( FULC ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Alexander Sapir - CEO, President & Director Alan Musso - Chief Financial Officer Iain Fraser - Senior Vice President of Early Development Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Matthew Biegler - Oppenheimer & Co. Inc., Research Division Andres Maldonado - H.C. Wainwright & Co, LLC, Research Division Luca Issi - RBC Capital Markets, Research Division Tazeen Ahmad - BofA Securities, Research Division Presentation Operator Good morning, and welcome to the Fulcrum Therapeutics Third Quarter 2025 Financial Results and Business Update Conference Call [Operator Instructions] This call is being webcast live and can be accessed on the Investors section of Fulcrum's website at www.fulcrumtx.com and is being recorded.
Oct 29, 2025 | seekingalpha.com
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) of the PIONEER trial; on track to provide data from the 20 mg dose cohort by year-end ― ― Ended Q3 2025 with $200.6 million in cash, cash equivalents, and marketable securities; cash runway into 2028 ― CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today reported financial results for the third quarter of 2025 and provided a business update.
Oct 29, 2025 | www.globenewswire.com
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2025 financial results will be released on Wednesday, October 29, 2025, before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Oct 22, 2025 | www.globenewswire.com
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to new employees. Fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employees entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
Oct 10, 2025 | www.globenewswire.com

Fulcrum's Email Address Formats

Fulcrum uses at least 2 format(s):

Fulcrum Email Formats	Example	Percentage
FLast@fulcrum-nh.com	JDoe@fulcrum-nh.com	100%

Frequently Asked Questions

Where is Fulcrum's headquarters located?

Fulcrum's main headquarters is located at 5 Tech Circle, Amherst, NH 03031, US. The company has employees across 2 continents, including North AmericaAsia.

What is Fulcrum's phone number?

You can contact Fulcrum's main corporate office by phone at

+1-603-673-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Fulcrum's stock symbol?

Fulcrum is a publicly traded company; the company's stock symbol is FULC.

What is Fulcrum's official website and social media links?

Fulcrum's official website is fulcrumnh.com and has social profiles on LinkedIn.

What is Fulcrum's NAICS code?

Fulcrum's NAICS code is 23 - Construction.

How many employees does Fulcrum have currently?

As of October 2025, Fulcrum has approximately 37 employees across 2 continents, including North AmericaAsia. Key team members include Chief Financial Officer: P. B.President: D. L.President: J. G.. Explore Fulcrum's employee directory with LeadIQ.

What industry does Fulcrum belong to?

Fulcrum operates in the Construction industry.

What is Fulcrum's email format?

Fulcrum's email format typically follows the pattern of FLast@fulcrum-nh.com. Find more Fulcrum email formats with LeadIQ.

When was Fulcrum founded?

Fulcrum was founded in 1989.

Fulcrum

Q: What is Fulcrum's official website and social media links?

Fulcrum's official website is fulcrumnh.com. Fulcrum has social profiles on LinkedIn.

Q: How many employees does Fulcrum have currently?

Fulcrum has approximately 37 employees.

ConstructionUnited States11-50 Employees

Fulcrum Associates is a construction management firm based in Amherst, NH that has been building a solid reputation in the construction industry since 1989.  Integrity, knowledge, experience, and quality workmanship combined with respect for our clients has enabled us to grow to become a well-respected member of the construction community.

OUR CORE VALUES

We strive to maintain clients and to produce a job that we are proud to have our name on. We also hold true to the fair and equitable treatment of all team members and stake holders. Our last core value consists of a fair profit, made only after we fulfill our first three values. These values are the key differentiators between our firm and the rest of the industry.